ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1181

Tocilizumab in Aortitis: A Multicenter Study of 79 Patients

Mónica Calderón-Goercke1, Javier Loricera 2, DIANA PRIETO- PENA 3, Vicente Aldasoro Caceres 4, Santos Castañeda 5, Ignacio Villa 6, Alicia Humbría 7, Clara Moriano 8, Susana Romero-Yuste 9, Javier Narváez 10, Catalina Gómez-Arango 11, Eva Perez Pampín 12, Rafael Melero 13, Marcelino Revenga 14, Noelia Álvarez-Rivas 15, Francisca Sivera 16, María Álvarez del buergo 17, Luisa Marena-Rojas 18, Eva Galindez-Agirregoikoa 19, Beatriz Arca 20, Roser Solans-Laqué 21, Carlos Vazquez 22, Pau Lluch 23, Eva salgado-Pérez 24, Cristina Luna-Gómez 25, F. Javier Toyos-Sáenz De Miera 26, Nagore Fernández-Llanio 27, Antonio García 28, Carmen Larena 29, Lara Sanchez-Bilbao 1, Iñigo Gonzalez-Mazon 3, Natalia Palmou-Fontana 3, Vanesa Calvo-Río 1, Carmen González-Vela 1, Alfonso Corrales 30, María Varela-García 4, Elena Aurrecoechea 6, Raquel Dos Santos 31, Sabela Fernández 20, Jose Luis Hernández 1, Miguel Angel González-Gay 32 and Ricardo Blanco 33, 1Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, 2Rheumatology Department. Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, 3Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 4Complejo Hospitalario de Navarra, Navarra, Navarra, Spain, 5Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, 6Hospital de Sierrallana, Torrelavega, Cantabria, Spain, 7Hospital de La Princesa, Madrid, Madrid, Spain, 8Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, 9Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, 10Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, 11Hospital Alto Deba, Mondragon, Pais Vasco, Spain, 12Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Santiago de Compostela, Spain, 13Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, 14Hospital Ramón y Cajal, Madrid, Madrid, Spain, 15Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, 16Hospital General Universitario de Elda, Elda, Spain, 17Hospital Río Carrión, Palencia, Castilla y Leon, Spain, 18Hospital La Mancha Centro, Alcázar de San Juan, Castilla-La Mancha, Spain, 19Hospital de Basurto, Bilbao, Pais Vasco, Spain, 20Hospital Universitario San Agustín, Avilés, Asturias, Spain, 21Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain., Barcelona, Catalonia, Spain, 22Hospital Miguel Servet, Zaragoza, Aragon, Spain, 23Hospital Mateu Orfila, Menorca, Islas Baleares, Spain, 24Complejo Hospitalario Universitario de Ourense, Ourense, Galicia, Spain, 25Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Canarias, Spain, 26Hospital Universitario Virgen Macarena, Sevilla, Andalucia, Spain, 27Hospital Arnau de Vilanova, Lérida, Catalonia, Spain, 28Hospital Virgen de las Nieves, Granada, Andalucia, Spain, 29Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, 30Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, 31Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Galicia, Spain, 32Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 33Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: aortitis, tocilizumab and efficacy

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Session Title: Imaging Of Rheumatic Diseases Poster II

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Aortitis can be idiopathic or associated with other conditions. It is frequently refractory to conventional immunosuppressive therapy. Tocilizumab (TCZ), an anti-IL-6 receptor antibody seems to be effective and safe.
Our aim was to assess the efficacy and safety of TCZ at short and long follow-up in a series of patients with Aortitis.

Methods: Retrospective, multicenter study of 79 patients diagnosed of inflammatory aortitis based on imaging techniques (PET/CT, CT angiography and/or MR angiography).

Results: We study 79 patients (61 w/ 18 m). 59 (74.7%) cases were Aortitis secondary to Giant Cell Arteritis (GCA), while 20 (25.3%) were idiopathic. The mean age was 71±8.5 years vs 64.2±7.1 years, respectively (p=0.001). At time of disease diagnosis more than a half of patients (59.5%) presented as main symptom polymyalgia rheumatica (PMR). Aortitis was diagnosed with PET/CT (71 patients), angioRMN (12 patients) and angioCT (8 patients). Prior to TCZ treatment, 61 (77.2%) patients had received conventional immunosuppressive drugs, 59 (74.7%) of them received MTX. After 24 months of treatment with TCZ, more than 75% of patients reached a prolonged remission in both groups (p=0.527), with only 4% of relapses after the same follow-up period (p=1.000). 40 (50.6%) patients had a control image technique (PET/CT) throughout follow up. 4 (3 secondary to GCA and 1 idiopathic) patients reached a complete improvement in uptake after one year of treatment.

Conclusion: Our results show that idiopathic aortitis occurs in younger patients compared with aortitis secondary to GCA. TCZ proved to be effective in both pathologies, allowing clinical and analytical improvement, as well as a reduction of corticoid dose, without increasing the risk of relapse. However, the improvement in imaging techniques seems to be slower.


TABLE Aortitis


Disclosure: M. Calderón-Goercke, None; J. Loricera, None; D. PRIETO- PENA, None; V. Aldasoro Caceres, None; S. Castañeda, None; I. Villa, None; A. Humbría, None; C. Moriano, None; S. Romero-Yuste, None; J. Narváez, None; C. Gómez-Arango, None; E. Perez Pampín, None; R. Melero, None; M. Revenga, None; N. Álvarez-Rivas, None; F. Sivera, None; M. Álvarez del buergo, None; L. Marena-Rojas, None; E. Galindez-Agirregoikoa, None; B. Arca, None; R. Solans-Laqué, None; C. Vazquez, None; P. Lluch, None; E. salgado-Pérez, None; C. Luna-Gómez, None; F. Toyos-Sáenz De Miera, None; N. Fernández-Llanio, None; A. García, None; C. Larena, None; L. Sanchez-Bilbao, None; I. Gonzalez-Mazon, None; N. Palmou-Fontana, None; V. Calvo-Río, None; C. González-Vela, None; A. Corrales, None; M. Varela-García, None; E. Aurrecoechea, None; R. Dos Santos, None; S. Fernández, None; J. Hernández, None; M. González-Gay, AbbVie, 2, 5, 8, Abbvie, 2, 5, 8, Celgene, 5, 8, Eli Lilly, 2, 5, EliLilly, 2, 5, Jansen, 2, Janssen, 2, MSD, 2, 5, 8, Novartis, 2, 5, Pfizer, 5, 8, Roche, 2, 5, 8, Sanofi, 2, 5, 8, Sobi, 5, 8; R. Blanco, None.

To cite this abstract in AMA style:

Calderón-Goercke M, Loricera J, PRIETO- PENA D, Aldasoro Caceres V, Castañeda S, Villa I, Humbría A, Moriano C, Romero-Yuste S, Narváez J, Gómez-Arango C, Perez Pampín E, Melero R, Revenga M, Álvarez-Rivas N, Sivera F, Álvarez del buergo M, Marena-Rojas L, Galindez-Agirregoikoa E, Arca B, Solans-Laqué R, Vazquez C, Lluch P, salgado-Pérez E, Luna-Gómez C, Toyos-Sáenz De Miera F, Fernández-Llanio N, García A, Larena C, Sanchez-Bilbao L, Gonzalez-Mazon I, Palmou-Fontana N, Calvo-Río V, González-Vela C, Corrales A, Varela-García M, Aurrecoechea E, Dos Santos R, Fernández S, Hernández J, González-Gay M, Blanco R. Tocilizumab in Aortitis: A Multicenter Study of 79 Patients [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/tocilizumab-in-aortitis-a-multicenter-study-of-79-patients/. Accessed June 1, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tocilizumab-in-aortitis-a-multicenter-study-of-79-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences